技术资料
-
Takei M et al. (OCT 1998) Antimicrobial agents and chemotherapy 42 10 2678--81Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.
We determined the inhibitory activities of gatifloxacin against Staphylococcus aureus topoisomerase IV,Escherichia coli DNA gyrase,and HeLa cell topoisomerase II and compared them with those of several quinolones. The inhibitory activities of quinolones against these type II topoisomerases significantly correlated with their antibacterial activities or cytotoxicities (correlation coefficient [r] = 0.926 for S. aureus,r = 0.972 for E. coli,and r = 0.648 for HeLa cells). Gatifloxacin possessed potent inhibitory activities against bacterial type II topoisomerases (50% inhibitory concentration [IC50] = 13.8 microg/ml for S. aureus topoisomerase IV; IC50 = 0.109 microg/ml for E. coli DNA gyrase) but the lowest activity against HeLa cell topoisomerase II (IC50 = 265 microg/ml) among the quinolones tested. There was also a significant correlation between the inhibitory activities of quinolones against S. aureus topoisomerase IV and those against E. coli DNA gyrase (r = 0.969). However,the inhibitory activity against HeLa cell topoisomerase II did not correlate with that against either bacterial enzyme. The IC50 of gatifloxacin for HeLa cell topoisomerase II was 19 and was more than 2,400 times higher than that for S. aureus topoisomerase IV and that for E. coli DNA gyrase. These ratios were higher than those for other quinolones,indicating that gatifloxacin possesses a higher selectivity for bacterial type II topoisomerases. View Publication -
Bhatia M et al. (SEP 1998) Nature medicine 4 9 1038--45A newly discovered class of human hematopoietic cells with SCID-repopulating activity.
The detection of primitive hematopoietic cells based on repopulation of immune-deficient mice is a powerful tool to characterize the human stem-cell compartment. Here,we identify a newly discovered human repopulating cell,distinct from previously identified repopulating cells,that initiates multilineage hematopoiesis in NOD/SCID mice. We call such cells CD34neg-SCID repopulating cells,or CD34neg-SRC. CD34neg-SRC are restricted to a Lin-CD34-CD38- population without detectable surface markers for multiple lineages and CD38 or those previously associated with stem cells (HLA-DR,Thy-1 and CD34). In contrast to CD34+ subfractions,Lin-CD34-CD38- cells have low clonogenicity in short-and long-term in vitro assays. The number of CD34neg-SRC increased in short-term suspension cultures in conditions that did not maintain SRC derived from CD34+ populations,providing independent biological evidence of their distinctiveness. The identification of this newly discovered cell demonstrates complexity of the organization of the human stem-cell compartment and has important implications for clinical applications involving stem-cell transplantation. View Publication -
Li Y et al. (AUG 1998) Molecular and cellular biology 18 8 4719--31Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines.
6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN or CD437),originally identified as a retinoic acid receptor gamma-selective retinoid,was previously shown to induce growth inhibition and apoptosis in human breast cancer cells. In this study,we investigated the role of AHPN/CD437 and its mechanism of action in human lung cancer cell lines. Our results demonstrated that AHPN/CD437 effectively inhibited lung cancer cell growth by inducing G0/G1 arrest and apoptosis,a process that is accompanied by rapid induction of c-Jun,nur77,and p21(WAF1/CIP1). In addition,we found that expression of p53 and Bcl-2 was differentially regulated by AHPN/CD437 in different lung cancer cell lines and may play a role in regulating AHPN/CD437-induced apoptotic process. On constitutive expression of the c-JunAla(63,73) protein,a dominant-negative inhibitor of c-Jun,in A549 cells,nur77 expression and apoptosis induction by AHPN/CD437 were impaired,whereas p21(WAF1/CIP1) induction and G0/G1 arrest were not affected. Furthermore,overexpression of antisense nur77 RNA in A549 and H460 lung cancer cell lines largely inhibited AHPN/CD437-induced apoptosis. Thus,expression of c-Jun and nur77 plays a critical role in AHPN/CD437-induced apoptosis. Together,our results reveal a novel pathway for retinoid-induced apoptosis and suggest that AHPN/CD437 or analogs may have a better therapeutic efficacy against lung cancer. View Publication -
Cheng ZJ et al. (JUN 1998) Biochimica et biophysica acta 1392 2-3 291--9Antioxidant properties of butein isolated from Dalbergia odorifera.
The antioxidant properties of butein,isolated from Dalbergia odorifera T. Chen,were investigated in this study. Butein inhibited iron-induced lipid peroxidation in rat brain homogenate in a concentration-dependent manner with an IC50,3.3+/-0.4 microM. It was as potent as alpha-tocopherol in reducing the stable free radical diphenyl-2-picrylhydrazyl (DPPH) with an IC0.200,9.2+/-1.8 microM. It also inhibited the activity of xanthine oxidase with an IC50,5.9+/-0.3 microM. Besides,butein scavenged the peroxyl radical derived from 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH) in aqueous phase,but not that from 2,2-azobis(2,4-dimethylvaleronitrile) (AMVN) in hexane. Furthermore,butein inhibited copper-catalyzed oxidation of human low-density lipoprotein (LDL),as measured by conjugated dienes and thiobarbituric acid-reactive substance (TBARS) formations,and electrophoretic mobility in a concentration-dependent manner. Spectral analysis revealed that butein was a chelator of ferrous and copper ions. It is proposed that butein serves as a powerful antioxidant against lipid and LDL peroxidation by its versatile free radical scavenging actions and metal ion chelation. View Publication -
Abe O et al. (MAY 1998) Lancet (London,England) 351 9114 1451--67Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
BACKGROUND There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer,and an updated overview of their results is presented. METHODS In 1995,information was sought on each woman in any randomised trial that began before 1990 of adjuvant tamoxifen versus no tamoxifen before recurrence. Information was obtained and analysed centrally on each of 37000 women in 55 such trials,comprising about 87% of the worldwide evidence. Compared with the previous such overview,this approximately doubles the amount of evidence from trials of about 5 years of tamoxifen and,taking all trials together,on events occurring more than 5 years after randomisation. FINDINGS Nearly 8000 of the women had a low,or zero,level of the oestrogen-receptor protein (ER) measured in their primary tumour. Among them,the overall effects of tamoxifen appeared to be small,and subsequent analyses of recurrence and total mortality are restricted to the remaining women (18000 with ER-positive tumours,plus nearly 12000 more with untested tumours,of which an estimated 8000 would have been ER-positive). For trials of 1 year,2 years,and about 5 years of adjuvant tamoxifen,the proportional recurrence reductions produced among these 30000 women during about 10 years of follow-up were 21% (SD 3),29% (SD 2),and 47% (SD 3),respectively,with a highly significant trend towards greater effect with longer treatment (chi2(1)=52.0,2ptextless0.00001). The corresponding proportional mortality reductions were 12% (SD 3),17% (SD 3),and 26% (SD 4),respectively,and again the test for trend was significant (chi2(1) = 8.8,2p=0.003). The absolute improvement in recurrence was greater during the first 5 years,whereas the improvement in survival grew steadily larger throughout the first 10 years. The proportional mortality reductions were similar for women with node-positive and node-negative disease,but the absolute mortality reductions were greater in node-positive women. In the trials of about 5 years of adjuvant tamoxifen the absolute improvements in 10-year survival were 10.9% (SD 2.5) for node-positive (61.4% vs 50.5% survival,2ptextless0.00001) and 5.6% (SD 1.3) for node-negative (78.9% vs 73.3% survival,2ptextless0.00001). These benefits appeared to be largely irrespective of age,menopausal status,daily tamoxifen dose (which was generally 20 mg),and of whether chemotherapy had been given to both groups. In terms of other outcomes among all women studied (ie,including those with ER-poor" tumours) View Publication -
Conneally E et al. (MAY 1998) Blood 91 9 3487--93Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential.
Recent studies have shown efficient gene transfer to primitive progenitors in human cord blood (CB) when the cells are incubated in retrovirus-containing supernatants on fibronectin-coated dishes. We have now used this approach to achieve efficient gene transfer to human CB cells with the capacity to regenerate lymphoid and myeloid progeny in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. CD34(+) cell-enriched populations were first cultured for 3 days in serum-free medium containing interleukin-3 (IL-3),IL-6,granulocyte colony-stimulating factor,Flt3-ligand,and Steel factor followed by two 24-hour incubations with a MSCV-NEO virus-containing medium obtained under either serum-free or serum-replete conditions. The presence of serum during the latter 2 days made no consistent difference to the total number of cells,colony-forming cells (CFC),or long-term culture-initiating cells (LTC-IC) recovered at the end of the 5-day culture period,and the cells infected under either condition regenerated similar numbers of human CD34(+) (myeloid) CFC and human CD19(+) (B lymphoid) cells for up to 20 weeks in NOD/SCID recipients. However,the presence of serum increased the viral titer in the producer cell-conditioned medium and this was correlated with a twofold to threefold higher efficiency of gene transfer to all progenitor types. With the higher titer viral supernatant,17% +/- 3% and 17% +/- 8%,G418-resistant in vivo repopulating cells and LTC-IC were obtained. As expected,the proportion of NEO + repopulating cells determined by polymerase chain reaction analysis of in vivo generated CFC was even higher (32% +/- 10%). There was no correlation between the frequency of gene transfer to LTC-IC and colony-forming unit-granulocyte-macrophage (CFU-GM),or to NOD/SCID repopulating cells and CFU-GM (r2 = 0.16 and 0.17,respectively),whereas values for LTC-IC and NOD/SCID repopulating cells were highly and significantly correlated (r2 = 0.85). These findings provide further evidence of a close relationship between human LTC-IC and NOD/SCID repopulating cells (assessed using a textgreater/= 6-week CFC output endpoint) and indicate the predictive value of gene transfer measurements to such LTC-IC for the design of clinical gene therapy protocols. View Publication -
Kordon EC and Smith GH (MAY 1998) Development (Cambridge,England) 125 10 1921--30An entire functional mammary gland may comprise the progeny from a single cell.
Any epithelial portion of a normal mouse mammary gland can reproduce an entire functional gland when transplanted into an epithelium-free mammary fat pad. Mouse mammary hyperplasias and tumors are clonal dominant populations and probably represent the progeny of a single transformed cell. Our study provides evidence that single multipotent stem cells positioned throughout the mature fully developed mammary gland have the capacity to produce sufficient differentiated progeny to recapitulate an entire functional gland. Our evidence also demonstrates that these stem cells are self-renewing and are found with undiminished capacities in the newly regenerated gland. We have taken advantage of an experimental model where mouse mammary tumor virus infects mammary epithelial cells and inserts a deoxyribonucleic acid copy(ies) of its genome during replication. The insertions occur randomly within the somatic genome. CzechII mice have no endogenous nucleic acid sequence homology with mouse mammary tumor virus; therefore all viral insertions may be detected by Southern analysis provided a sufficient number of cells contain a specific insertional event. Transplantation of random fragments of infected CzechII mammary gland produced clonal-dominant epithelial populations in epithelium-free mammary fat pads. Serial transplantation of pieces of the clonally derived outgrowths produced second generation glands possessing the same viral insertion sites providing evidence for self-renewal of the original stem cell. Limiting dilution studies with cell cultures derived from third generation clonal outgrowths demonstrated that three multipotent but distinct mammary epithelial progenitors were present in clonally derived mammary epithelial populations. Estimation of the potential number of multipotent epithelial cells that may be evolved from an individual mammary-specific stem cell by self-renewal is in the order of 10(12)-10(13). Therefore,one stem cell might easily account for the renewal of mammary epithelium over several transplant generations. View Publication -
Miller CL and Eaves CJ (DEC 1997) Proceedings of the National Academy of Sciences of the United States of America 94 25 13648--53Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability.
Elucidation of mechanisms that regulate hematopoietic stem cell self-renewal and differentiation would be facilitated by the identification of defined culture conditions that allow these cells to be amplified. We now demonstrate a significant net increase (3-fold,P textless 0.001) in vitro of cells that are individually able to permanently and competitively reconstitute the lymphoid and myeloid systems of syngeneic recipient mice when Sca-1(+)lin- adult marrow cells are incubated for 10 days in serum-free medium with interleukin 11,flt3-ligand,and Steel factor. Moreover,the culture-derived repopulating cells continued to expand their numbers in the primary hosts at the same rate seen in recipients of noncultured stem cells. In the expansion cultures,long-term culture-initiating cells increased 7- +/- 2-fold,myeloid colony-forming cells increased 140- +/- 36-fold,and total nucleated cells increased 230- +/- 62-fold. Twenty-seven of 100 cultures initiated with 15 Sca-1(+)lin- marrow cells were found to contain transplantable stem cells 10 days later. This frequency of positive cultures is the same as the frequency of transplantable stem cells in the original input suspension,suggesting that most had undergone at least one self-renewal division in vitro. No expansion of stem cells was seen when Sca-1+TER119- CD34+ day 14.5 fetal liver cells were cultured under the same conditions. These findings set the stage for further investigations of the mechanisms by which cytokine stimulation may elicit different outcomes in mitotically activated hematopoietic stem cells during ontogeny and in the adult. View Publication -
Carroll M et al. (DEC 1997) Blood 90 12 4947--52CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selectively kills p210BCR-ABL-expressing cells. To extend these observations,we evaluated the ability of CGP 57148 to inhibit other activated ABL tyrosine kinases,including p185BCR-ABL and TEL-ABL. In cell-based assays of ABL tyrosine phosphorylation,inhibition of ABL kinase activity was observed at concentrations similar to that reported for p210BCR-ABL. Consistent with the in vitro profile of this compound,the growth of cells expressing activated ABL protein tyrosine kinases was inhibited in the absence of exogenous growth factor. Growth inhibition was also observed with a p185BCR-ABL-positive acute lymphocytic leukemia (ALL) cell line generated from a Philadelphia chromosome-positive ALL patient. As CGP 57148 inhibits the PDGFR kinase,we also showed that cells expressing an activated PDGFR tyrosine kinase,TEL-PDGFR,are sensitive to this compound. Thus,this compound may be useful for the treatment of a variety of BCR-ABL-positive leukemias and for treatment of the subset of chronic myelomonocytic leukemia patients with a TEL-PDGFR fusion protein. View Publication -
Bertolini F et al. (OCT 1997) Blood 90 8 3027--36Multilineage long-term engraftment potential of drug-resistant hematopoietic progenitors.
Peripheral blood progenitor cells (PBPCs) are increasingly used instead of bone marrow for autologous or allogeneic transplantation. In this study PBPCs mobilized in cancer patients by chemotherapy and granulocyte-colony stimulating factor were collected by apheresis and first enriched by immunoaffinity removal of lineage positive cells. When these cells were exposed to both cyclophosphamide and taxol or cultured for 7 days in the presence of 5-fluorouracil,stem cell factor,and interleukin-3,88% to 93% of the enriched PBPCs were killed and short-term clonogenic capacity in methylcellulose assays was lost,but week-5 cobblestone area-forming cell (CAFC) enrichment was higher than 10-fold in comparison to enriched PBPCs and higher than 700-fold in comparison to unmanipulated apheresis cells. After drug exposure,most of the progenitors displayed a CD34+,CD38-,multidrug-resistance (MDR+),Rhodamine 123 low,Hoechst 33342 low phenotype,and as few as 180 of these drug-resistant cells were able to generate a stable multilineage human hematopoiesis in sublethally irradiated immunodeficient mice. In these animals,the level of human hematopoietic engraftment was significantly increased by cotransplantation of irradiated cells from the human L87/4 stromal cell line. These observations are consistent with the functional isolation of a population of very early hematopoietic progenitors and might help to design new protocols for the removal of neoplastic cells from autografts. View Publication -
Mulatero P et al. (NOV 1997) Hypertension 30 5 1274--8Impaired cortisol binding to glucocorticoid receptors in hypertensive patients.
We compared glucocorticoid receptor binding characteristics and glucocorticoid responsiveness of human mononuclear leukocytes (HML) from hypertensive patients and matched normotensive volunteers. We also considered associations of these variables with plasma renin activity,aldosterone,cortisol,corticotropin,and electrolyte concentrations. We calculated binding affinity (Kd; nmol/L) and capacity (Bmax; sites/cell) for dexamethasone and cortisol from homologous and heterologous competition curves for specific [3H]dexamethasone binding sites on HML isolated from the blood of normotensive volunteers and subjects with essential hypertension. Glucocorticoid responsiveness of HML was evaluated as IC50 values (nmol/L) for dexamethasone and cortisol for the inhibition of lysozyme release. We measured plasma hormones by radioimmunoassay. Kd values (mean+/-SE) for cortisol in HML of hypertensive patients were higher than in control subjects (24.6+/-2.4 versus 17.5+/-1.7 nmol/L,Ptextless.04). Binding capacity (4978+/-391 versus 4131+/-321 sites/cell),Kd values for dexamethasone (6.7+/-0.5 versus 5.7+/-0.3 nmol/L),and IC50 values for dexamethasone (3.4+/-0.3 versus 3.1+/-0.2 nmol/L) and cortisol (12.2+/-1.6 versus 9.5+/-0.3 nmol/L) were not significantly different. Patients with renin values less than 0.13 ng angiotensin I/L per second were markedly less sensitive to cortisol than those with higher values. Both Kd (30.3+/-2.5 versus 19.2+/-2.4 nmol/L) and IC50 values (15.5+/-1.8 versus 8.9+/-1.2 nmol/L) for cortisol were significantly higher in patients with lower renin values (Ptextless.03). Other variables,including plasma hormone and electrolyte values and binding characteristics for dexamethasone,were not different. These data suggest that cortisol binding to glucocorticoid receptor is slightly impaired in patients with essential hypertension. In vivo,this could lead to inappropriate binding of cortisol to mineralocorticoid receptors. Hence,decreased sensitivity to cortisol is associated with renin suppression. This hypothesis is supported by evidence of hypertension and low renin activity,which others have described in patients with primary glucocorticoid resistance due to mutations of the glucocorticoid receptor. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 70 项目
- HLA 52 项目
- 上皮细胞生物学 269 项目
- 免疫 1012 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 48 项目
- 嵌合体 25 项目
- 干细胞生物学 2827 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 7 项目
- 新陈代谢 7 项目
- 杂交瘤制备 2 项目
- 疾病建模 248 项目
- 癌症 6 项目
- 神经科学 650 项目
- 移植研究 100 项目
- 类器官 178 项目
- 细胞外囊泡研究 10 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 113 项目
- 细胞系制备 191 项目
- 脐带血库 64 项目
- 血管生成细胞研究 1 项目
- 传染病 64 项目
- 内皮细胞生物学 7 项目
- 杂交瘤生成 14 项目
- 癌症研究 724 项目
- 血管生成细胞研究 51 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 11 项目
- CellShield 1 项目
- CellSTACK 1 项目
- DermaCult 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ES-Cult 78 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- Maestro 2 项目
- Matrigel 2 项目
- MegaCult 37 项目
- STEMprep 11 项目
- ALDEFLUOR 237 项目
- AggreWell 82 项目
- ArciTect 38 项目
- BloodStor 2 项目
- BrainPhys 84 项目
- CellAdhere 3 项目
- ClonaCell 107 项目
- CloneR 9 项目
- CryoStor 75 项目
- EC-Cult 1 项目
- EasySep 963 项目
- EpiCult 15 项目
- HemaTox 4 项目
- HepatiCult 32 项目
- Hypothermosol 1 项目
- ImmunoCult 39 项目
- IntestiCult 213 项目
- Lymphoprep 12 项目
- MammoCult 45 项目
- MesenCult 164 项目
- MethoCult 499 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 373 项目
- NeuroFluor 3 项目
- PBS-MINI 8 项目
- PancreaCult 11 项目
- PneumaCult 119 项目
- RSeT 13 项目
- ReLeSR 10 项目
- RoboSep 43 项目
- RosetteSep 268 项目
- STEMdiff 193 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 38 项目
- SmartDish 1 项目
- StemSpan 251 项目
- TeSR 1545 项目
- ThawSTAR 5 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 229 项目
- CD4+ 46 项目
- CD8+ 29 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 162 项目
- PSC衍生 37 项目
- T 细胞 441 项目
- 上皮细胞 143 项目
- 中胚层 5 项目
- 乳腺细胞 95 项目
- 先天性淋巴细胞 32 项目
- 全血 10 项目
- 其他子集 1 项目
- 其他细胞系 10 项目
- 内皮细胞 11 项目
- 内胚层 4 项目
- 前列腺细胞 18 项目
- 单个核细胞 93 项目
- 单核细胞 178 项目
- 多能干细胞 1986 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 21 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 92 项目
- 树突状细胞(DCs) 118 项目
- 气道细胞 4 项目
- 淋巴细胞 73 项目
- 癌细胞及细胞系 149 项目
- 癌细胞和细胞系 1 项目
- 白细胞 24 项目
- 白细胞单采样本 13 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 465 项目
- 神经细胞 12 项目
- 粒细胞及其亚群 96 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 40 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 27 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血浆 3 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 调节性细胞 10 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 968 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 25 项目
- 间充质干/祖细胞 188 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 3 项目
- 骨髓基质细胞 1 项目
- 骨髓间质细胞 2 项目
- 髓系细胞 135 项目
- 肾脏细胞 8 项目
- CD4+T细胞 100 项目
- CD8+T细胞 86 项目
- PSC衍生上皮细胞 39 项目
- PSC衍生中胚层 25 项目
- PSC衍生内皮细胞 20 项目
- PSC衍生内胚层 28 项目
- PSC衍生心肌细胞 26 项目
- PSC衍生神经细胞 130 项目
- PSC衍生肝细胞 18 项目
- PSC衍生造血干细胞 39 项目
- PSC衍生间充质细胞 27 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 96 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 17 项目
- 神经元 201 项目
- 调节性T细胞 59 项目
- 骨髓瘤 5 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号